Last month, we stopped by Fina Biosolutions and caught up with Founder, CEO and Chief Scientific Officer, Dr. Andrew Lees.

Fina Biosolutions is a privately held company providing technology, laboratory and consulting services in the field of conjugate vaccines and has been an active MTC member for five years. Chemistry developed by Fina Biosolutions’ scientists is used by MTC members, GSK and Pfizer, among others.

Since our visit, Fina Biosolutions LLC announced it had reached an agreement with PATH, a global organization focused on solving some of the world’s most pressing health challenges, under which PATH will provide funding and technical support for the clinical manufacture of FinaBio’s CRM₁₉₇, known commercially as EcoCRM^®.  “This agreement will allow us to support the development of urgently needed vaccines,” Mark Alderson, director of PATH’s pneumococcus, meningitis, and group B Streptococcus projects said. “It’s just one example of how public-private partnerships can save lives and foster commercial development at the same time.” Read more here.

Contact:
Fina Biosolutions LLC
Dr. Andrew Lees, 301-633-0464
ALees@Finabio.com